ArticleThoracic cancer2023
Epidemiological landscape of esophageal cancer in Asia: Results from GLOBOCAN 2020.
Article in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A Systematic Mapping Review of Core Outcome Reporting in Surgical Research for Oesophageal Cancer.Journal of surgical oncology · 2026Pooled it
- Association between the HALP score and survival of patients with esophageal or gastro-esophageal junction cancer: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Efficacy and safety of neoadjuvant chemotherapy with immunotherapy versus chemotherapy alone in esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials.Frontiers in immunology · 2026Pooled it
- Global burden of esophageal cancer attributable to smoking and alcohol, 1990-2021, with projections to 2040: a population-based analysis of the global burden of disease study 2021.Annals of medicine · 2026Observational
- Mapping the global landscape of robot-assisted minimally invasive esophagectomy (RAMIE): a bibliometric and visualized study.Journal of robotic surgery · 2026Article
- AI-driven multi-omics drug repurposing nominates AZD7762 as a multitarget inhibitor of IL22RA1 and FAM221A in esophageal squamous cell carcinoma.NPJ precision oncology · 2026Article
- CD172aBMC gastroenterology · 2026Article
- The prevalence, nature and trajectory of oropharyngeal dysphagia within the first year following curative open resection for esophageal cancer.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2026Article
- Postoperative chemoradiotherapy for esophageal squamous cell Carcinoma: Results from ESO-Shanghai 17 and joint analyses for phase II clinical trials.Clinical and translational radiation oncology · 2026Article
- A decade of esophageal cancer in Kazakhstan: what the national cancer registry reveals (2014-2023).Frontiers in oncology · 2026Article
- Machine learning survival prediction in esophageal cancer using radiomics and body composition from pretreatment and follow-up T12-level computed tomography.World journal of gastrointestinal oncology · 2025Article
- Targeting ferroptosis in cancer stem cells: A novel strategy to improve cancer treatment.Genes & diseases · 2025Review
- Tumor Microvessels with Specific Morphology as a Prognostic Factor in Esophageal Squamous Cell Carcinoma.Annals of surgical oncology · 2025Article
- Tailoring treatment for esophageal cancer: a retrospective comparison of chemoradiation with and without esophagectomy.BMC surgery · 2025Article
- CT-Based Habitat Radiomics Combining Multi-Instance Learning for Early Prediction of Post-Neoadjuvant Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma.Bioengineering (Basel, Switzerland) · 2025Article
- Article
- The prevalence, nature and severity of oropharyngeal dysphagia in the acute post-operative phase following curative resection for esophageal cancer.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025Article
- Chemotherapy May Influence Esophageal Lugol Chromoendoscopy Severity: A Retrospective Cohort Study and Literature Review.The Kaohsiung journal of medical sciences · 2025Review
- Long-term use of low-dose aspirin for cancer prevention: A 20-year longitudinal cohort study of 1,506,525 Hong Kong residents.International journal of cancer · 2025Article
- Exploring novel immunotherapy in advanced esophageal squamous cell carcinoma: Is targeting TIGIT an answer?Esophagus : official journal of the Japan Esophageal Society · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal cancer (EC) is a global health problem. Asia represents a huge burden of EC globally, and incidence and mortality vary considerably across different Asian regions.
methodsData on incidence, mortality, and preference were extracted from GLOBOCAN 2020. Age-standardized incidence and mortality rates were calculated overall by sex, age, country, region, and continent. The predicted burden of incidence and mortality in 2040 was calculated based on global demographic projections.
resultsIt was estimated there were 481 552 new cases of and 434 363 deaths from EC in Asia in 2020, accounting for 79.7% and 79.8% of world EC cases and deaths, respectively. EC incidence and mortality in Asia ranked the highest among all continents. Eastern Asia represents the highest age-standardized world incidence rate (ASWIR) of 12.3 per 100 000 for all Asian regions. Western Asia represents the lowest ASWIR of 1.7 per 100 000, accounting for 0.7% of the globe. There exist obvious differences in epidemiological features in Asian countries, including incidence, mortality, prevalence, and mortality incidence ratio. There is forecast to be up to 781 000 new cases of EC in Asia by 2040, with increasing rates of 63% for incidence and 72% for mortality from 2020.
conclusionsAsia has an increasing number of EC cases and deaths. Strategies for targeting in high-incidence areas, the elderly, and survival should be prioritized to reduce the global EC burden, especially in low- and middle-income countries in Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.